Other Routine +

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

By The Northwire Desk — AI Analysis Jun 18, 2026 · 09:02 TRIP · 0.025 Red Light Holland Corp.

Executive Summary

Red Light Holland reports positive preclinical results from Magdalena Biosciences (a joint venture with Jaguar Health) for a novel whole-leaf coca extract.
The extract prevented weight gain in mice on a high-fat diet without suppressing appetite or increasing physical activity, targeting post-GLP-1 weight maintenance.
Development is advancing under the FDA's Botanical Guidance pathway. The 20-day study was conducted at the University of Calgary using legally sourced Peruvian coca leaves.
Corporate structure: Magdalena is a U.S.-based JV formed in 2023 by Filament Health (wholly owned by Red Light) and Jaguar Health.
Funding: One Small Planet (founded by Will Peterffy) committed US$1,000,000 to the JV.
Strategic context: Red Light is leveraging its April 2026 acquisition of Filament Health to expand into pharmaceutical-grade manufacturing, regulatory compliance, and clinical research for botanical medicines.

Material Impact

The news is a preclinical milestone, not an earnings release. It confirms pipeline progress for a novel weight-maintenance therapy targeting the large post-GLP-1 market.
The stock had already run +200% into the print, implying the market expected continued pipeline validation and M&A integration benefits.
The $1M JV funding from One Small Planet is modest and does not materially change the cash runway.
The underlying facts are positive but incremental. The market reaction (not in data) will likely be muted or negative if the stock fails to hold the $0.03 level, given the high expectations baked in.
The news is Routine - Positive. It reinforces the strategic pivot but does not alter the fundamental risk/reward profile or provide near-term revenue visibility.

TRIP · Price

Company Overview

Red Light Holland Corp. (CSE: TRIP) is a Canadian company that has pivoted from consumer retail (mushroom grow kits, functional gummies) to a regulated psychedelic and botanical drug development platform.
Core assets include Filament Health's patented botanical psilocybin candidate PEX010, a Health Canada Level 8 Dealer's Licence, GMP manufacturing capabilities, and a portfolio of 76 patents.
The company supplies PEX010 to 80+ global academic and clinical studies, focusing on depression, PTSD, substance use disorders, and cancer-related distress.
Recent strategic moves include the acquisition of Filament Health (April 2026), partnerships with Kala Bio for AI-driven clinical planning, and the formation of Magdalena Biosciences for a coca extract weight-maintenance program.

More from Red Light Holland Corp.